XML 72 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Segments of Business (Tables)
 6 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended September 30,
 
Six Months Ended September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Revenues
 
 
 
 
 
 
 
U.S. Pharmaceutical and Specialty Solutions (1)
$
45,979

 
$
41,610

 
$
90,144

 
$
82,587

European Pharmaceutical Solutions (1)
6,598

 
6,639

 
13,308

 
13,574

Medical-Surgical Solutions (1)
2,056

 
1,948

 
3,959

 
3,651

Other
2,983

 
2,878

 
5,933

 
5,870

Total Revenues
$
57,616

 
$
53,075

 
$
113,344

 
$
105,682

 
 
 
 
 
 
 
 
Operating profit (loss) (2)
 
 
 
 
 
 
 
U.S. Pharmaceutical and Specialty Solutions (3)
$
639

 
$
610

 
$
1,218

 
$
1,153

European Pharmaceutical Solutions (4)
1

 
10

 
6

 
(550
)
Medical-Surgical Solutions
129

 
105

 
254

 
198

Other (5) (6)
(1,311
)
 
95

 
(1,170
)
 
209

Total
(542
)
 
820

 
308

 
1,010

Corporate Expenses, Net (7)
(364
)
 
(167
)
 
(539
)
 
(290
)
Interest Expense
(64
)
 
(66
)
 
(120
)
 
(127
)
Income (Loss) from Continuing Operations Before Income Taxes
$
(970
)
 
$
587

 
$
(351
)
 
$
593

 
 
 
 
 
 
 
 
Revenues, net by geographic area
 
 
 
 
 
 
 
United States
$
48,292

 
$
43,774

 
$
94,614

 
$
86,664

Foreign
9,324

 
9,301

 
18,730

 
19,018

Total Revenues
$
57,616

 
$
53,075

 
$
113,344

 
$
105,682

(1)
Revenues derived from services represent less than 1% of our U.S. Pharmaceutical and Specialty Solutions segment’s total revenues, less than 10% of our European Pharmaceutical Solutions segment’s total revenues and less than 2% of our Medical-Surgical Solutions segment’s total revenues.
(2)
Segment operating profit (loss) includes gross profit, net of operating expenses, as well as other income (expense), net, for our operating segments.
(3)
Our U.S. Pharmaceutical and Specialty Solutions segment’s operating profit for the second quarter and first six months of 2020 includes $33 million and $48 million, and for the second quarter and first six months of 2019 includes $22 million and $43 million pre-tax credits related to our last-in, first-out (“LIFO”) method of accounting for inventories. Operating profit for the first six months of 2019 also includes $35 million of cash receipts for our share of antitrust legal settlements.
(4)
European Pharmaceutical Solutions segment’s operating profit for the first six months of 2019 includes non-cash goodwill impairment charges of $570 million (pre-tax and after-tax).
(5)
Operating profit (loss) for Other for the second quarter and first six months of 2019 includes pre-tax restructuring, impairment and related charges of $42 million and $80 million primarily associated with the closure of retail pharmacy stores within our Canadian business. The first six months of 2019 include escrow settlement gain of $97 million (pre-tax and after-tax) representing certain indemnity and other claims related to our 2017 third quarter acquisition of Rexall Health.
(6)
Operating profit (loss) for Other for the second quarter and first six months of 2020 includes pre-tax impairment charge of $1,157 million and a pre-tax dilution loss of $246 million associated with our investment in Change Healthcare JV. Operating profit (loss) for Other for the second quarter and first six months of 2019 includes a pre-tax credit of $90 million representing the derecognition of the TRA liability payable to the shareholders of Change Healthcare Inc. Operating profit (loss) for Other also includes our proportionate share of loss from Change Healthcare JV of $51 million and $47 million for the second quarter and first six months of 2020 and $56 million and $112 million for the second quarter and first six months of 2019.
(7)
Corporate expenses, net, for the second quarter and first six months of 2020 include pre-tax settlement charges of $105 million and $122 million from the termination of our defined benefit pension plan and a settlement charge of $82 million (pre-tax and after-tax) related to opioid claims. The second quarter and first six months of 2020 includes $36 million and $72 million, and for the second quarter and first six months of 2019 includes $43 million and $59 million pre-tax charges of opioid-related costs, primarily litigation expenses.